FDA To Rescind A 510(k): Rare Action Targets ReGen's Menaflex Device
This article was originally published in The Gray Sheet
Executive Summary
FDA says it will seek to rescind a much-scrutinized 510(k) clearance of an implantable knee device, initiating a rarely used regulatory authority that some in industry argue does not exist.
You may also be interested in...
CDRH Drops Seven Divisive 510(k) Proposals; Congress Picks Some Up
The device center is dropping seven controversial 510(k) reform-related proposals, including creating a “class IIb” category of devices, following pushback from industry. But some of the matters are under consideration on Capitol Hill.
ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge
ReGen Biologics says it is considering several last-ditch options to keep its collagen meniscus scaffold device on the U.S. market, but they do not include another hearing with FDA.
ReGen Declines "Futile" 510(k) Rescission Hearing But Plans Legal Challenge
ReGen Biologics says it is considering several last-ditch options to keep its collagen meniscus scaffold device on the U.S. market, but they do not include another hearing with FDA.